In this second episode of the four-part series, Haider Warraich discusses integrating heart failure (HF) care with palliative care, answers questions submitted via social media, and offers tips on how to navigate the conversation about palliative care with patients with HF.

In this first episode of the four-part series, Haider Warraich defines the clinical diagnosis of heart failure, including its causes, symptoms, and management, and palliative care, which he differentiates from hospice care.

In this podcast, Kim Birtcher, Seth Martin, Donald Lloyd-Jones, and Lynne Braun discuss what optimal lipid therapy and management look like in a post-ezetimibe world. They answer patient and colleague questions about lowering low-density lipoprotein (LDL) and debate if LDL can ever be too low. This is a rebroadcast from the clinical focus session at ACC.19.

In this podcast, Naomi Hamburg discusses risk assessment and peripheral arterial disease (PAD) therapies in patients. Identification of PAD, exercise interventions, and pharmacotherapy are examined. This is a rebroadcast from the clinical focus session at ACC.19.

In this podcast, Kimberly Guibone and Zachary Goldberger discuss the future of syncope care. The current state of care, syncope centers, and accurate diagnosis of patients are examined. This is a rebroadcast from the clinical focus session at ACC.19.

This podcast discusses the article "Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-REAL 2 Study." The multinational study explores real world evidence on the use of sodium-glucose cotransporter-2. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the cardioprotective effects of new drug classes will prepare you to better treat your patients.

This podcast discusses the risks and benefits of starting new diabetes therapies on a patient with type 2 diabetes. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the cardioprotective effects of new drug classes will prepare you to better treat your patients.

This podcast discusses monitoring patients who have been started on a new diabetes therapy, such as sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide 1 receptor agonists. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the cardioprotective effects of new drug classes will prepare you to better treat your patients.

This podcast discusses the article "Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis." As the incidence of type 2 diabetes mellitus rises in the United States, understanding the cardioprotective effects of new drug classes will prepare you to better treat your patients. Learn how the classification of diabetes mellitus has changed from describing a homogenous group to a heterogeneous group and how that affects treatment.

This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.